Nakajima H, Kita Y, Takashi T, Akasaki M, Yamaguchi F, Ozawa S, Tsukada W, Abe S, Mizuno D
Gan. 1984 Mar;75(3):260-8.
The immunopharmacological behavior of DMG, an antitumor polysaccharide, was studied in mice. DMG administered ip or sc stimulated peritoneal macrophages to produce high levels of interleukin-1 activity, which can amplify successive immune responses. DMG dose-dependently and schedule-dependently increased the cellular immune response against allogeneic tumor cells and the humoral immune response to sheep erythrocytes. DMG also enhanced nonspecific antitumor effector functions, such as natural killer activity of spleen and peritoneal cells, and the cytostatic activity of peritoneal macrophages. Peritoneal macrophages activated by ip or sc injection of DMG exhibited high cytostatic activity, especially after exposure in vitro to lymphokine supernatants containing macrophage activation factor. Moreover, granulocyte/macrophage colony-stimulating activity in the serum increased 2-10 hr after DMG administration. Thus, DMG potentiated antigen-specific immunological functions and nonspecific functions of host defense systems against cancer both qualitatively and quantitatively.
对一种抗肿瘤多糖DMG在小鼠体内的免疫药理行为进行了研究。腹腔注射或皮下注射DMG可刺激腹腔巨噬细胞产生高水平的白细胞介素-1活性,白细胞介素-1可放大后续免疫反应。DMG剂量依赖性和给药方案依赖性地增强了针对同种异体肿瘤细胞的细胞免疫反应以及对绵羊红细胞的体液免疫反应。DMG还增强了非特异性抗肿瘤效应功能,如脾脏和腹腔细胞的自然杀伤活性以及腹腔巨噬细胞的细胞抑制活性。腹腔注射或皮下注射DMG激活的腹腔巨噬细胞表现出高细胞抑制活性,尤其是在体外暴露于含有巨噬细胞激活因子的淋巴因子上清液后。此外,DMG给药后2 - 10小时血清中的粒细胞/巨噬细胞集落刺激活性增加。因此,DMG在质量和数量上均增强了宿主防御系统针对癌症的抗原特异性免疫功能和非特异性功能。